Dendritic cell vaccination for metastatic melanoma: A 14-year monoinstitutional experience

Francesco De Rosa, Laura Ridolfi, Laura Fiammenghi, Massimiliano Petrini, Anna M. Granato, Valentina Ancarani, Elena Pancisi, Valentina Soldati, Serena Cassan, Jenny Bulgarelli, Massimo Framarini, Francesca Tauceri, Giuseppe Migliori, Claudia Brolli, Giorgia Gentili, Elisabetta Petracci, Oriana Nanni, Angela Riccobon, Ruggero Ridolfi, Massimo Guidoboni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and are very well tolerated, but their effectiveness has yet to be demonstrated. We have been treating patients with advanced melanoma with an autologous dendritic cell vaccine since 2001; to better characterize the safety and efficacy of our product, we designed a retrospective study on all of our patients treated with the vaccine to date. We retrospectively reviewed both case report forms of patients included in clinical trials and medical records of those treated within a compassionate use program. Response was assessed according to the Response Evaluation Criteria In Solid Tumors criteria and toxicity has been graded according to CTCAE 4.0. Although the response rate has been rather low, the median overall survival of 11.4 months and the 1-year survival rate of 46.9% are encouraging, especially considering the fact that data were obtained in a heavily pretreated population and only about one quarter of the patients had received ipilimumab and/or BRAF inhibitors. Multivariate analysis confirmed that the development of an immune response was significantly correlated with a better prognosis (hazard ratio 0.54; P=0.019). The adverse events observed were generally mild and self-limiting. Our analysis confirms the excellent tolerability of our vaccine, making it a potential candidate for combination therapies. As efficacy seems largely restricted to immunoresponsive patients, future strategies should aim to increase the number of these patients.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalMelanoma Research
Volume27
Issue number4
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Dendritic Cells
Melanoma
Vaccination
Vaccines
Compassionate Use Trials
Medical Records
Multivariate Analysis
Survival Rate
Retrospective Studies
Clinical Trials
T-Lymphocytes
Safety
Survival
Antibodies
Population

Keywords

  • Active
  • cancer vaccines
  • dendritic cells
  • immunotherapy
  • melanoma

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Dendritic cell vaccination for metastatic melanoma : A 14-year monoinstitutional experience. / De Rosa, Francesco; Ridolfi, Laura; Fiammenghi, Laura; Petrini, Massimiliano; Granato, Anna M.; Ancarani, Valentina; Pancisi, Elena; Soldati, Valentina; Cassan, Serena; Bulgarelli, Jenny; Framarini, Massimo; Tauceri, Francesca; Migliori, Giuseppe; Brolli, Claudia; Gentili, Giorgia; Petracci, Elisabetta; Nanni, Oriana; Riccobon, Angela; Ridolfi, Ruggero; Guidoboni, Massimo.

In: Melanoma Research, Vol. 27, No. 4, 01.01.2017, p. 351-357.

Research output: Contribution to journalArticle

De Rosa, F, Ridolfi, L, Fiammenghi, L, Petrini, M, Granato, AM, Ancarani, V, Pancisi, E, Soldati, V, Cassan, S, Bulgarelli, J, Framarini, M, Tauceri, F, Migliori, G, Brolli, C, Gentili, G, Petracci, E, Nanni, O, Riccobon, A, Ridolfi, R & Guidoboni, M 2017, 'Dendritic cell vaccination for metastatic melanoma: A 14-year monoinstitutional experience', Melanoma Research, vol. 27, no. 4, pp. 351-357. https://doi.org/10.1097/CMR.0000000000000356
De Rosa, Francesco ; Ridolfi, Laura ; Fiammenghi, Laura ; Petrini, Massimiliano ; Granato, Anna M. ; Ancarani, Valentina ; Pancisi, Elena ; Soldati, Valentina ; Cassan, Serena ; Bulgarelli, Jenny ; Framarini, Massimo ; Tauceri, Francesca ; Migliori, Giuseppe ; Brolli, Claudia ; Gentili, Giorgia ; Petracci, Elisabetta ; Nanni, Oriana ; Riccobon, Angela ; Ridolfi, Ruggero ; Guidoboni, Massimo. / Dendritic cell vaccination for metastatic melanoma : A 14-year monoinstitutional experience. In: Melanoma Research. 2017 ; Vol. 27, No. 4. pp. 351-357.
@article{6e911108ebba4ae8898d25fe298174f1,
title = "Dendritic cell vaccination for metastatic melanoma: A 14-year monoinstitutional experience",
abstract = "Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and are very well tolerated, but their effectiveness has yet to be demonstrated. We have been treating patients with advanced melanoma with an autologous dendritic cell vaccine since 2001; to better characterize the safety and efficacy of our product, we designed a retrospective study on all of our patients treated with the vaccine to date. We retrospectively reviewed both case report forms of patients included in clinical trials and medical records of those treated within a compassionate use program. Response was assessed according to the Response Evaluation Criteria In Solid Tumors criteria and toxicity has been graded according to CTCAE 4.0. Although the response rate has been rather low, the median overall survival of 11.4 months and the 1-year survival rate of 46.9{\%} are encouraging, especially considering the fact that data were obtained in a heavily pretreated population and only about one quarter of the patients had received ipilimumab and/or BRAF inhibitors. Multivariate analysis confirmed that the development of an immune response was significantly correlated with a better prognosis (hazard ratio 0.54; P=0.019). The adverse events observed were generally mild and self-limiting. Our analysis confirms the excellent tolerability of our vaccine, making it a potential candidate for combination therapies. As efficacy seems largely restricted to immunoresponsive patients, future strategies should aim to increase the number of these patients.",
keywords = "Active, cancer vaccines, dendritic cells, immunotherapy, melanoma",
author = "{De Rosa}, Francesco and Laura Ridolfi and Laura Fiammenghi and Massimiliano Petrini and Granato, {Anna M.} and Valentina Ancarani and Elena Pancisi and Valentina Soldati and Serena Cassan and Jenny Bulgarelli and Massimo Framarini and Francesca Tauceri and Giuseppe Migliori and Claudia Brolli and Giorgia Gentili and Elisabetta Petracci and Oriana Nanni and Angela Riccobon and Ruggero Ridolfi and Massimo Guidoboni",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CMR.0000000000000356",
language = "English",
volume = "27",
pages = "351--357",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Dendritic cell vaccination for metastatic melanoma

T2 - A 14-year monoinstitutional experience

AU - De Rosa, Francesco

AU - Ridolfi, Laura

AU - Fiammenghi, Laura

AU - Petrini, Massimiliano

AU - Granato, Anna M.

AU - Ancarani, Valentina

AU - Pancisi, Elena

AU - Soldati, Valentina

AU - Cassan, Serena

AU - Bulgarelli, Jenny

AU - Framarini, Massimo

AU - Tauceri, Francesca

AU - Migliori, Giuseppe

AU - Brolli, Claudia

AU - Gentili, Giorgia

AU - Petracci, Elisabetta

AU - Nanni, Oriana

AU - Riccobon, Angela

AU - Ridolfi, Ruggero

AU - Guidoboni, Massimo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and are very well tolerated, but their effectiveness has yet to be demonstrated. We have been treating patients with advanced melanoma with an autologous dendritic cell vaccine since 2001; to better characterize the safety and efficacy of our product, we designed a retrospective study on all of our patients treated with the vaccine to date. We retrospectively reviewed both case report forms of patients included in clinical trials and medical records of those treated within a compassionate use program. Response was assessed according to the Response Evaluation Criteria In Solid Tumors criteria and toxicity has been graded according to CTCAE 4.0. Although the response rate has been rather low, the median overall survival of 11.4 months and the 1-year survival rate of 46.9% are encouraging, especially considering the fact that data were obtained in a heavily pretreated population and only about one quarter of the patients had received ipilimumab and/or BRAF inhibitors. Multivariate analysis confirmed that the development of an immune response was significantly correlated with a better prognosis (hazard ratio 0.54; P=0.019). The adverse events observed were generally mild and self-limiting. Our analysis confirms the excellent tolerability of our vaccine, making it a potential candidate for combination therapies. As efficacy seems largely restricted to immunoresponsive patients, future strategies should aim to increase the number of these patients.

AB - Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and are very well tolerated, but their effectiveness has yet to be demonstrated. We have been treating patients with advanced melanoma with an autologous dendritic cell vaccine since 2001; to better characterize the safety and efficacy of our product, we designed a retrospective study on all of our patients treated with the vaccine to date. We retrospectively reviewed both case report forms of patients included in clinical trials and medical records of those treated within a compassionate use program. Response was assessed according to the Response Evaluation Criteria In Solid Tumors criteria and toxicity has been graded according to CTCAE 4.0. Although the response rate has been rather low, the median overall survival of 11.4 months and the 1-year survival rate of 46.9% are encouraging, especially considering the fact that data were obtained in a heavily pretreated population and only about one quarter of the patients had received ipilimumab and/or BRAF inhibitors. Multivariate analysis confirmed that the development of an immune response was significantly correlated with a better prognosis (hazard ratio 0.54; P=0.019). The adverse events observed were generally mild and self-limiting. Our analysis confirms the excellent tolerability of our vaccine, making it a potential candidate for combination therapies. As efficacy seems largely restricted to immunoresponsive patients, future strategies should aim to increase the number of these patients.

KW - Active

KW - cancer vaccines

KW - dendritic cells

KW - immunotherapy

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=85021790525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021790525&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000356

DO - 10.1097/CMR.0000000000000356

M3 - Article

AN - SCOPUS:85021790525

VL - 27

SP - 351

EP - 357

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -